Introduction
Gene therapy for treating genetic disorders has recently become a major research focus. Transgene-based gene therapy, in which a viral vector carrying cDNA is used, is a commonly used approach that has been successful in correcting X-linked severe combined immunodeficiency (SCID) (Cavazzana-Calvo et al. 2000; Hacein-Bey-Abina et al. 2002; Gaspar et al. 2003) and SCID due to a deficiency of the adenosine deaminase enzyme (Blaese et al. 1995; Onodera et al. 1998; Muul et al. 2003) . However, this type of gene therapy is not suited to treating genetic disorders caused by deficiency in a gene that requires intrinsic regulation. In this case, it would be ideal to introduce a genomic fragment containing its own regulatory element. For example, hyperimmunoglobulin (Ig)M syndrome (HIGM) is a genetic disorder caused by deficiency in a gene encoding the CD40 ligand, which requires intrinsic regulation. HIGM is a rare, X-linked, recessive immunodeficiency disease characterized by the failure of IgM to undergo immunoglobulin-isotype switching to IgG, IgA, and IgE (Kroczek et al. 1994) . The CD40 ligand is a cell-surface ligand expressed by CD4 + T cells, the expression of which is regulated by cell activation (DiSanto et al. 1993; Korthauer et al. 1993; Roy et al. 1993) . Functionally, CD40L gene mutation results in dysfunctional interactions between CD4 + T cells and the CD40 glycoprotein on the surfaces of B cells, macrophages, and dendritic cells (Stout et al. 1996; Grewal and Flavell 1998; Straw et al. 2003) . Gene therapy for this condition was demonstrated to be feasible by Brown et al. (1998) using ex vivo retrovirus-mediated gene transfer of cDNA to bone marrow cells in a mouse CD40L-knockout model. Although this approach corrected the CD40L deficiency and stimulated humoral and cellular immune functions, the mice developed T-lymphoproliferative disease. This suggests that nonintrinsic overexpression of CD40L may cause abnormal proliferative responses, resulting in T-lymphoproliferative disease. Thus, an alternative gene-delivery system that permits regulated transgene expression is required for HIGM gene therapy (Brown et al. 1998) .
As described elsewhere, we recently developed a novel human artificial chromosome (HAC) vector (Katoh et al. 2004) . The HAC vector has several advantages over conventional vectors such as viruses and plasmids: there is no limitation on the size of DNA fragment that can be inserted, the HAC is independently and stably maintained, and the copy number is strictly controlled. Thus, the HAC vector containing a genomic fragment has the potential to permit intrinsic expression of transgenes (Grimes et al. 2002; Larin and Mejia 2002; Saffery and Choo 2002) In this study, we used an HAC vector to carry a CD40L genomic fragment and examined cell-type-specific gene expression and the function of the exogenous CD40L gene.
Materials and methods

Cell culture
Chinese hamster ovary (CHO) cells were maintained in Ham's F-12 nutrient mixture (Wako) containing 10% FBS (FBS) (Bio West). A human CD4-positive active T-cell line (Jurkat) and a human myeloid cell line (U937) were maintained in Roswell Park Memorial Institute (RPMI)-1640 (Wako) containing 10% FBS (Bio West). We used these human cell lines to analyze expression of the mCD40L gene on the HAC vector for the following reasons. First, the cells used in this study must continue to proliferate over the long term, long enough to obtain clones containing HAC by microcell-mediated chromosome transfer (MMCT) and to carry out further analyses. Second, expression of the mCD40L gene on the HAC vector must be discriminated from expression of the endogenous CD40L gene in cells. Third, since human CD40L does not bind to mouse CD40 (Bossen et al. 2006 ), using human cell lines as hosts meant that we could study the function of the mCD40L genomic fragment introduced via the HAC vector. A total of 3 9 10 5 B cells that had been obtained from the spleens of CD40L -/-mice (Jackson Laboratory) were cultured with the same number of Jurkat-mCD40L-HAC cells. These cells were treated with mitomycin C (Sigma) in RPMI-1640 containing 10% FBS (Bio West), 0.05 mM 2-ME (Sigma), 500 U/ml mrIL-4 (R&D Systems) and 150 U/ml mrIL-5 (R&D Systems).
Subcloning the mouse CD40L genome into a PAC vector A bacterial artificial chromosome (BAC) clone, RP23-153G22 (BACPAC Resource Center, Oakland, CA, USA), was used to clone a mouse CD40L genomic fragment (21,342 bp) into a pPAC4 vector carrying a loxP-site and the cytomegalovirus (CMV) promoter. The gap repair cassette DNA was amplified by polymerase chain reaction (PCR) using the primers 5 0 -AAGGATCCCACTTAAA CAGAAGCCACACCCAGCTCTTTCATTGCAGAGAGA TGTCTTCGAGCTCTTGGGGGA-3 0 and 5 0 -TTGGATCC GGTTGAGGTTGGAAATTTTAGCTAGTCCACTCGCA TCAGCCTTCCCCCAAGAGCTCGAAGAC-3 0 and cloned into the BamHI site of pPAC4 to create a subcloning vector. The subcloning vector contained 5 0 and 3 0 regions that were homologous to those of the mouse CD40L genome. A homologous recombination-proficient Escherichia coli strain, DY380 (kindly provided by Dr. Donald Court, National Cancer Institute, Frederick, MD, USA), was used for the BAC engineering (Lee et al. 2001 ).
Construction of an HAC vector carrying the mouse CD40L genomic fragment in CHO cells
Twelve micrograms of the PAC vector containing the mouse CD40L genome and 0.3 lg of the Cre expression vector pBS185 (Life Technologies) were transformed into 5 9 10 5 CHO cells containing the 21Dpq HAC vector (Katoh et al. 2004 ) using Lipofectamine 2000 , and transformed cells were selected using G418 (Invitrogen). G418-resistant colonies were isolated, and insertion of the mCD40L genomic fragment into the loxP site of the HAC vector was confirmed by genomic PCR with three primer pairs, as follows ( 
Fluorescence in situ hybridization (FISH) analysis
Metaphase chromosomes were prepared from exponentially growing cell cultures, and fluorescence in situ hybridization (FISH) was carried out using standard protocols. The probes used were digoxigenin-labeled human Cot1 DNA (Invitrogen; digoxigenin from Roche), biotin-labeled mouse CD40L DNA (biotin from Roche), and digoxigenin-labeled hchr21 alphoid DNA. The digoxigenin signal was detected using an anti-digoxigenin-rhodamine complex (Roche), and the biotin signal was detected using an avidin-fluorescein isothiocyanate (adivin-FITC) (Roche) complex. The chromosomes were counterstained with 4',6-diamidino-2-phenylindole (DAPI) (Sigma). Images were captured using an optical microscope (Nikon) equipped a Configuration of mouse CD40L gene. ''+1'' corresponds to the transcription start site. The 5 0 and 3 0 untranslated regions are indicated by lighter-color boxes. We referred to a previous report (Cron 2002) to draw this diagram. b A flowchart of this study: A circular targeting construct carrying the mouse CD40L genomic fragment and the nonfunctional loxP-neo target on the HAC vector is shown. The Cre recombinase-catalyzed integration regenerates a functional neogene. The resulting inserted allele is shown at the bottom. Arrowheads indicate the genomic polymerase chain reaction (PCR) primers used for detection of the site-specific insertion. c The site-specific insertion event was detected by genomic PCR. The numbers 1-3 correspond to the number of the primer pair used. The 100-bp DNA ladder with a photometric charge-coupled device (CCD) camera and visualized using the Argus system (Hamamatsu Photonics).
Microcell-mediated chromosome transfer (MMCT)
The mCD40L-HAC vector remaining in the CHO cells was transferred to 1 9 10 7 Jurkat or U937 cells via microcellmediated chromosome transfer (MMCT), as previously described (Doherty and Fisher 2003; Katoh et al. 2004; Kakeda et al. 2005) .
Flow cytometry analysis
Cells carrying mCD40L-HAC were stained with FITClabeled anti-mouse-CD154 (Santa Cruz) and PE-labeled anti-human-CD154 (BioLegend) and then analyzed by flow cytometry (Beckman Coulter).
Reverse transcriptase polymerase chain reaction (RT-PCR) analysis
Expression of the mCD40L gene on the HAC vector in human cells was detected by reverse transcriptase PCR (RT-PCR) with primer pairs: F, 5 0 -AGAGAATTA CAGGGCAGGCA-3 0 and R, 5 0 -TTGAGCTGAGGCTCA-CAGTTG-3 0 . These primer pairs detect a 3 0 UTR region of mCD40L.
Enzyme-linked immunosorbent assay (ELISA) B cells and Jurkat-mCD40L-HAC cells were cocultured for 7 days, then the concentration of mouse IgG secreted into the culture medium was analyzed using enzyme-linked immunosorbent assay (ELISA) with horseradish-peroxidase-labeled anti-mouse-IgG (Amersham Biosciences).
Results
Construction of the mCD40L-HAC vector in CHO cells
The mouse gene encoding the CD40 ligand was obtained together with a 4-kb upstream and a 5-kb downstream DNA sequence. The gene was cloned by gap repair from BAC clone RP23-153G22 into a pPAC4 vector carrying a loxP sequence and the CMV promoter. This promoter drove expression of the promoterless neogene in the HAC vector after site-specific recombination. The integrity of the constructs was confirmed by PCR and restriction enzyme analysis (data not shown). The resulting construct and Cre-expression vector pBS185 were cotransfected into CHO carrying an HAC vector. After selection using G418, site-specific insertion of the mCD40L genomic fragment into the HAC vector was confirmed using genomic PCR (Fig. 1b, c) and FISH analysis using the Cot1 and mCD40L gene probes (Fig. 1d) . The yield of CHO cells carrying mCD40L-HAC was *5 9 10 -5 . The mCD40L gene on the HAC vector was not expressed in CHO cells (data not shown). These results showed that the mCD40L gene was inserted into the loxP-site on the HAC vector by Cre-mediated recombination in the expected manner and that the construct existed as a mitotically stable extraminichromosome.
Expression of the mCD40L gene on the HAC vector in human cells
To investigate how the mCD40L gene on the HAC vector was expressed in different cells, the mCD40L-HAC vector was transferred from CHO into cells of the Jurkat (human CD4-positive active T-cell line) and U937 (human myeloid cell line) lines by MMCT. FACS analysis showed that about 10% of the Jurkat cells expressed human CD40L, whereas the U937 cells did not express human CD40L at all (data not shown). After selection using G418, the G418-resistant clones were confirmed to carry mCD40L-HAC using genomic PCR (Fig. 2a) . The transfer efficiency was *2.4 9 10 -5 , and a total of 42 Jurkat clones carrying mCD40L-HAC were obtained. Twenty clones carrying the mCD40L-HAC vector were used for subsequent analyses. FISH analyses using hchr21 alphoid DNA or mouse CD40L genomic DNA as a probe showed that the mCD40L-HAC vector was maintained independently (Fig. 2b, c) and that the retention rate was more than 94% for each clone (n = 50 for each clone). Ten U937 clones carrying the mCD40L-HAC vector were also obtained, and for these, the retention rate of the mCD40L-HAC vector was more than 96% for each clone (n = 50 for each clone).
Expression of the mCD40L gene on the HAC vector in Jurkat and U937 cells was analyzed by flow cytometry (Fig. 3a, b) . In the Jurkat cells carrying the mCD40L-HAC vector, an average of 8% of the cells (range 5-20%) expressed mCD40L. The percentage of cells expressing mCD40L (8%) was similar to the percentage of cells expressing hCD40L (10%). The percentage expressing both mCD40L and hCD40L was *1%, suggesting that CD40L is stochastically expressed in a proportion of Jurkat cells. The results of flow cytometry analysis suggested that expression levels of endogenous hCD40L and exogenous mCD40L in Jurkat cells are in a similar range, as expected. In contrast, the mCD40L gene on the HAC vector was not expressed in U937 cells (Fig. 3a) . The expression of mCD40L was confirmed by RT-PCR in Jurkat cells and U937 cells (Fig. 3c) . These results suggest that introduction of the mCD40L genomic fragment via an HAC vector permits cell-type-specific expression of mCD40L.
Functional analysis of the mCD40L gene introduced via the HAC vector
To investigate the function of the mCD40L gene introduced via the HAC vector, B cells obtained from CD40L knockout mice were cultured with Jurkat cells carrying the mCD40L-HAC vector or intact Jurkat cells as a control. After 7 days of coculture, the concentration of mouse IgG in the culture medium was analyzed using ELISA. In the medium in which mouse B cells and Jurkat cells with the mCD40L-HAC vector were cultured, mouse IgG was detected at a concentration of 6.8-9.8 lg/ml (Fig. 4) . In contrast, no IgG was detected in the medium in which mouse B cells and intact Jurkat cells were cultured. We prepared normal mouse T cells from C57BL/6. When these cells were stimulated by phorbol myristate acetate (PMA) and ionomycin, about 34% of the cells expressed CD40L. We used the stimulated cells as a positive control for the above assay system. IgG was detected at a concentration of 9.9-12.5 lg/ml. These results show that the mCD40L genomic fragment on the HAC vector functions to stimulate mouse B cells and induce the secretion of IgG in a similar fashion to activated normal mouse T cells.
Discussion
The results of this study suggest that introduction of a CD40L genomic fragment via an HAC vector permits celltype-specific expression and functions to stimulate mouse B cells, inducing secretion of IgG. The mCD40L-HAC was functional for mouse B cells obtained from CD40L knockout mice. Thus, mCD40L-HAC has the potential to correct the function of T cells with mutations in the gene encoding the CD40 ligand, the basis for gene therapy for HIGM. We showed that HAC vectors containing the hCD40L genomic fragment have the potential to be useful in gene-therapy-based treatment of HIGM. In this study, we tried unsuccessfully to introduce the mCD40L-HAC vector into primary T cells obtained from CD40L knockout mice. We assume that the reason for this is HAC being introduced into the cells with a very low efficiency. For ex vivo gene delivery to primary cells or somatic stem cells with a limited lifespan, improvements in efficiency are essential. An advantage of the HAC vector for gene therapy is that it can be maintained as an independent minichromosome without integration into the host genome. In this study, the mCD40L-HAC vector was maintained independently in all 20 Jurkat clones. This suggests that introduction of the mCD40L-HAC vector into cells will not cause insertional mutagenesis and that expression of the CD40L genome would not be subject to position effects. In a previous study, we confirmed the HAC vector is mitotically stable in human primary hematopoietic cells without selection (Yamada et al. 2006) . Thus, use of HAC vectors would be safe, causing no lesions in the host genome with introduction of the transgene, and would provide long-term transgene expression.
This study shows that, in combination with BAC/PAC recombineering technologies, the HAC vector enables the gene of interest to be delivered as a genomic fragment. This novel gene expression system has the potential to permit intrinsic regulation of the transgene. Also, a readymade genomic library with a YAC or BAC backbone or multiple genomic fragments can be loaded onto the HAC vector. Furthermore, a genomic fragment several Mb long can be loaded into the HAC vector using the Cre-loxPbased chromosome engineering technology (Kuroiwa et al. 2002) . In combination with these technologies, HAC vectors could be used to deliver genomic fragments more than 1 Mb in size.
We previously demonstrated that the HAC vector can be used for gene transfer into human fibroblast, hematopoietic, Fig. 4 Functional analysis of the mouse CD40L gene on the human artificial chromosome (HAC) vector. B cells obtained from CD40L knockout mice were cultured with Jurkat cells carrying mCD40L-HAC (five different clones), intact Jurkat cells, or the stimulated mouse T cells for a week, and then the culture medium was harvested. The concentration of mouse immunoglobulin (Ig)G in the culture medium was measured using enzyme-linked immunosorbent assay (ELISA) and mesenchymal stem cells, providing long-term expression of the therapeutic gene and conferring a growth advantage on cells carrying the vector (Kakeda et al. 2005; Ren et al. 2005; Yamada et al. 2006) . In this study, we addressed the use of the HAC vector for treating a genetic disorder caused by a gene deficiency, which requires intrinsic gene expression. This study is the first to support such an approach and represents a first step toward a novel gene therapy utilizing the HAC vector and BAC engineering. Further studies using this gene expression system, which utilizes the HAC vector carrying the therapeutic gene, will make the HAC vector a novel option for ex vivo gene therapy.
